nav

NAV-2729 inhibits six ArfGEFs (human ARNO, EFA6, BIG1, and BRAG2 and Legionella and Rickettsia RalF), the strongest effects being against BRAG2, Arf1 and Arf6.

Nav1.8-IN-1 (CHEMBL1270208) is an inhibitor of human NaV1.8

NaV1.7 inhibitor-1, an efficacious inhibitor of voltage-gated sodium channel (NaV) 1.7 (IC50 of 0.6 nM for hNaV1.7).

Nav1.7 blocker 1 (example 41), an effective Na+ channel (Na v) blocker, exhibits a potent IC50 value of 0.037 μM. This compound is utilized in pain research, encompassing neuropathic, postoperative, and inflammatory pain among others [1].

Nav1.7-IN-6, a selective inhibitor of Nav1.7.

Nav1.7-IN-3 is a selective and orally bioavailable inhibitor of voltage-gated sodium channel Nav1.7(IC50 of 8 nM).

Nav1.7 inhibitor is a potent inhibitor of Nav1.7.

Nav1.7-IN-8 is a highly potent and selective inhibitor of NaV1.7, exhibiting greater selectivity for inhibiting NaV1.7 compared to the subtypes hNaV1.1 and hNaV1.5. Additionally, Nav1.7-IN-8 has inhibitory effects on CYP2C9 and CYP3A4, with IC50 values of 0.17 μM and 0.077 μM, respectively. Notably, Nav1.7-IN-8 demonstrates significant analgesic properties in rodent models of both acute and inflammatory pain.

Nav1.8-IN-8 (Compound A11), a Nav1.8 channel inhibitor, potentially mitigates diseases mediated by sodium ion channels (NaV) [1].

Nav1.1 activator 1 is a highly potent activator of Nav1.1 with BBB penetration.

NAV26 is a selective blocker of the Nav1.7 channel.

NaV1.7 Blocker-801 is a potent NaV1.7 blocker.

Nav1.7-IN-2 is avoltage-gated sodium channels (Nav) inhibitor in particular Nav 1.7(IC50 of 80 nM).

Nav1.8-IN-5 (Example 1), a voltage-gated sodium channel Nav1.8 inhibitor, is applicable in the research of Nav1.8-mediated diseases including pain, pain-related disorders, and cardiovascular diseases (such as atrial fibrillation) [1].

Nav1.8-IN-4 is a potent Nav1.8 channel inhibitor with potential analgesic activity.Nav1.8-IN-4 can be used for pain and neurological related disorders.

Nav1.8-IN-14 (compound 20) is an effective selective inhibitor of Nav1.8. It is utilized in the research of pain-associated diseases.

Nav1.8-IN-7 (Example 116) serves as a selective inhibitor of Nav1.8, demonstrating more than 50% inhibition at 100 nM specifically for Nav1.8. It exhibits an IC50 of 15.6 μM for the hERG channel. This compound holds promise in the field of pain research [1].

Nav1.8-IN-13 (compound 16), functioning as a Nav1.8 inhibitor with a pIC50 value of 7.9, is referenced as [1].

Nav1.8-IN-2 (compound 35A) is a potent Nav1.8 inhibitor (IC50: 0.4 nM) and can be utilized in research on pain disorders, cough, and both acute and chronic pruritus.

Nav1.8-IN-11 (Example 1), a Nav1.8 channel inhibitor with an IC50 of 0.1 nM, is utilized in research on pain disorders [1].

Nav1.8-IN-9 (Example 16), a potent Nav1.8 inhibitor with an IC 50 of 0.084 nM, is orally active and holds promise for extensive pain research [1].

Nav1.3 Channel Inhibitor 1 (Compound 15b) is a state-dependent inhibitor of the voltage-gated sodium channel Na v 1.3, with an IC50 value of 20 nM. It has the ability to cross the blood-brain barrier, making it applicable for research into nervous system disorders [1].

Nav1.8-IN-10 (Compound 6), functioning as a Nav1.8 channel inhibitor, exhibits a 79.4% blocking rate of the Nav1.8 channel at a concentration of 4 nM. This compound is utilized in researching pain disorders [1].

Nav1.8-IN-12 (Compound 23 R) serves as an inhibitor of the Nav1.8 channel and is utilized in the research of pain-related diseases [1].

Nav1.1-IN-B is a selective NaV1.1 inhibitor which reduces visceral hypersensitivity.

NaV1.2 1.6 channel blocker-1 is a potent inhibitor of NaV1.2 and NaV1.6 channels, exhibiting inhibitory effects on rNaV1.6 and hNaV1.2. This compound can be utilized in the study of generalized epilepsy and movement disorders.

Inavolisib (GDC-0077) is an orally available selective PI3Kα inhibitor with an IC50 value of 0.038 nM.It exerts its activity by binding to the ATP-binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3.

Navitoclax (ABT-263) is a potent oral Bcl-2 inhibitor that binds to Bcl-xL, Bcl-2, and Bcl-w proteins (Ki<1 nM), demonstrating antitumor activity and inducing apoptosis.

Navtemadlin (AMG232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction (IC50: 0.6 nM). It binds to MDM2 with a Kd of 0.045 nM.

Darunavir (TMC114) is an HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.

Atazanavir sulfate (BMS-232632 sulfate) is an azapeptide and HIV-protease inhibitor used in the treatment of HIV infections and AIDS in combination with other anti-HIV agents.

Darunavir Ethanolate (UIC 94017) is an HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.

Atazanavir (BMS-232632)(BMS-232632) is an highly effective HIV-1 protease inhibitor.

Ritonavir (ABT 538) is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.

Pinaverium bromide is an calcium channel blocker with Antispasmodic and effectively relieves pain, diarrhea and intestinal discomfort.

Anavenol (2-(naphthalen-2-yloxy)ethanol) is an equine anesthetic.

The N-dealkylated metabolite (M1) of Atazanavir, a HIV protease inhibitor.

(Rac)-Telinavir shows anti-HIV activity.

Navamepent (RX-10045) is an analog of resolvin E1 (a dietary-3 polyunsaturated fatty acid metabolite), which has potent anti-inflammatory activity that reduces corneal inflammation, epithelial damage, and accelerates corneal tissue repair.Navamepent inhibits the release of several key pro-inflammatory mediators from corneal epithelial cells.Navamepent is very effective against dry eye and cupping cell loss Navamepent is effective against dry eye and cupping cell loss, and accelerates tear production.

Flutafuranol, also known as AZD 4694 and NAV4694, is a bio-active chemical. AZD4694 shows high affinity for beta-amyloid fibrils in vitro (K(d) = 2.3 +/- 0.3 nM). The fluorine-18 labeled AZD4694 may have potential for PET-visualization of cerebral beta-am

Lopinavir (ABT-378) is a peptidomimetic HIV protease inhibitor effective against HIV protease with the Val 82 mutation. It is less affected by serum protein binding compared to the structurally related drug ritonavir.

Navarixin (MK-7123)(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia.

Nelfinavir (AG1341) is an antiretroviral drug used in the treatment of the human immunodeficiency virus (HIV) (Ki=2 nM). Nelfinavir is a broad-spectrum, anticancer agent.

Cyfluthrin binds to voltage-sensitive sodium channel such as Nav 1.8 sodium channel and modify their gating kinetics, thereby disrupting nerve function of pests.

Proparacaine Hydrochloride is the hydrochloride salt form of proparacaine, a benzoic acid derivative with local anesthetic property. Proparacaine hydrochloride (Proparacaine HCl) stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting sodium ion influx required for the initiation and conduction of impulses within the neuronal cell, and resulting in a loss of sensation.

L-Canavanine sulfate is a selective inducible NO synthase inhibitor.

Fosamprenavir Calcium Salt (GW433908G) (GW433908G) is a phosphate ester prodrug of the antiretroviral protease inhibitor Amprenavir, with improved solubility. Fosamprenavir Calcium Salt has Anti-HIV infection.

Enavogliflozin (DWP-16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor.